Tibet Cheezheng Tibetan Medicine Co., Ltd.
Symbol: 002287.SZ
SHZ
22.21
CNYMarktpreis heute
20.1008
P/E-Verhältnis
0.0000
PEG-Verhältnis
11.78B
MRK Kapital
- 0.02%
DIV Rendite
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10005.55 | 2366.5 | 1976.9 | 1850.6 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 8430.88 | 1963 | 1539.3 | 1184 | ||||||||||||||||||
balance-sheet.row.net-receivables | 3258.11 | 663.5 | 841.2 | 629.6 | ||||||||||||||||||
balance-sheet.row.inventory | 642.83 | 156.3 | 127.8 | 118.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 87.71 | 8 | 246.6 | 337.7 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 14048.36 | 3194.4 | 3192.4 | 2936.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5861.27 | 1651.6 | 1144.4 | 821.4 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1413.28 | 351.6 | 374.8 | 399.3 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -561.9 | 1056.5 | -423.1 | -42.4 | ||||||||||||||||||
balance-sheet.row.tax-assets | 139.57 | 39.4 | 29.1 | 26.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 5055.39 | 4.9 | 1568.9 | 1426.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11907.61 | 3104.1 | 2694.2 | 2631.4 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.account-payables | 744.05 | 255.6 | 93.5 | 184 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 3466.68 | 478 | 762.3 | 610.8 | ||||||||||||||||||
balance-sheet.row.tax-payables | 237.12 | 55.6 | 61.9 | 37.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 4253.1 | 1061.3 | 934.4 | 841.4 | ||||||||||||||||||
Deferred Revenue Non Current | 754.86 | 191.3 | 167 | 154.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 127.94 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 460.38 | 437.7 | 402.2 | 4.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 4959.4 | 1089.2 | 1138.9 | 1039.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 21.98 | 7 | 4.9 | 4.9 | ||||||||||||||||||
balance-sheet.row.total-liab | 11067.61 | 2334.4 | 2499 | 2347.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 471.98 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 2120.75 | 530.2 | 530.2 | 530.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 8154.57 | 2104.1 | 1784.8 | 1667 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2375.97 | 631.3 | 566.4 | 507.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1369.17 | 454.7 | 454.6 | 464.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 14492.44 | 3720.3 | 3336 | 3169 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 25955.97 | 6298.5 | 5886.6 | 5567.8 | ||||||||||||||||||
balance-sheet.row.minority-interest | 202.02 | 49.8 | 51.6 | 51.4 | ||||||||||||||||||
balance-sheet.row.total-equity | 14694.46 | 3770.1 | 3387.7 | 3220.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 25955.97 | - | - | - | ||||||||||||||||||
Total Investments | 5660.63 | 3019.6 | 1116.2 | 1141.6 | ||||||||||||||||||
balance-sheet.row.total-debt | 7726.78 | 1546.3 | 1696.7 | 1452.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 6152.1 | 1142.9 | 1259.1 | 785.6 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 585.9 | 581.2 | 469.5 | 710.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 7.51 | 95.8 | 83.2 | 65.8 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -17.2 | -24.3 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0.87 | -168.3 | 3.6 | 4.9 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 38 | 47.8 | -374.7 | 521.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 41.95 | 42 | -209.3 | 369.7 | ||||||||||||||||||
cash-flows.row.inventory | -28.46 | -28.5 | -10.6 | -24 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 9.8 | -146.4 | 136.6 | ||||||||||||||||||
cash-flows.row.other-working-capital | 24.51 | 24.5 | -8.3 | 38.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 320.18 | 439.6 | 112.5 | -306.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 934.39 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.acquisitions-net | -0.56 | -0.6 | -3.8 | -61.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1450 | -1492.4 | -1418 | -3494.7 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1063.16 | 1138.1 | 1355.9 | 1526 | ||||||||||||||||||
cash-flows.row.other-investing-activites | -229.98 | 0 | 3.8 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -642.34 | -589.7 | -334.5 | -2155.4 | ||||||||||||||||||
cash-flows.row.debt-repayment | -1492.91 | -201.8 | -637.8 | -341.8 | ||||||||||||||||||
cash-flows.row.common-stock-issued | -250.46 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.5 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -219.61 | -206.7 | -340.5 | -195.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 1205.14 | -13.3 | 795.1 | 494.6 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -92.13 | -431.9 | -183.2 | -42.8 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.14 | 0.6 | 3 | -0.7 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 215.99 | -34.1 | -229.1 | -1164 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1573.63 | 403.4 | 437.6 | 666.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1357.64 | 437.6 | 666.6 | 1830.6 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 934.39 | 971.9 | 285.7 | 1034.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -254.94 | -234.8 | -272.4 | -125.6 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 679.46 | 737.1 | 13.3 | 909.3 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 2101.04 | 2010.3 | 2044.8 | 1770.5 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 349.53 | 382.4 | 324.1 | 265.3 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1751.51 | 1627.9 | 1720.6 | 1505.1 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 58 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 52.87 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 1191.78 | 1161.6 | 1118.9 | 1007.3 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1541.31 | 1544 | 1443.1 | 1272.6 | ||||||||||||||||||
income-statement-row.row.interest-income | 10.54 | 13.1 | 17 | 34.4 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1004.63 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -3.15 | 0.8 | 78 | 50.5 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 130.43 | 176.2 | -2.3 | -2.3 | ||||||||||||||||||
income-statement-row.row.interest-expense | 63.33 | 63.1 | 56.4 | 53.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 61.27 | 95.8 | 143.9 | 111 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 598.17 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 569.73 | 466.3 | 521.5 | 790.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 672.15 | 642.5 | 519.2 | 787.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 73.04 | 65.2 | 49.7 | 77.1 | ||||||||||||||||||
income-statement-row.row.net-income | 585.9 | 581.2 | 472.5 | 715.9 |
Häufig gestellte Frage
Wie hoch ist die Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) Gesamtvermögen?
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) Gesamtvermögen ist 6298478593.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 1150739074.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.834.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 1.281.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.279.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.271.
Was ist der Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 581198850.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 1546314759.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 1161615874.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 357241866.000.